{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:26:07Z","timestamp":1792463167010,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["GlaxoSmithKline"],"award-info":[{"award-number":["GlaxoSmithKline"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"DOI":"10.1007\/s10198-026-01968-7","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:08:31Z","timestamp":1786075711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of a single dose of the adjuvanted respiratory syncytial virus preFusion protein 3 vaccine over 5 years and its potential public health impact among older adults in Italy"],"prefix":"10.1007","author":[{"given":"Anna","family":"Puggina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Zarkadoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Rumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Marijam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisa","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"1968_CR1","doi-asserted-by":"publisher","first-page":"e1031","DOI":"10.1016\/S2214-109X(19)30264-5","volume":"7","author":"Y Li","year":"2019","unstructured":"Li, Y., R. M. Reeves, X. Wang, Q. Bassat, W. A. Brooks, and C. Cohen et al. 2019. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Global Health 7:e1031\u2013e1045.","journal-title":"Lancet Global Health"},{"key":"1968_CR2","doi-asserted-by":"publisher","first-page":"ofy316","DOI":"10.1093\/ofid\/ofy316","volume":"5","author":"EA Belongia","year":"2018","unstructured":"Belongia, E. A., J. P. King, B. A. Kieke, J. Pluta, A. Al-Hilli, and J. K. Meece et al. 2018. Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults\u2009\u2265\u200960 Years Old. Open Forum Infectious Diseases 5:ofy316.","journal-title":"Open Forum Infectious Diseases"},{"key":"1968_CR3","doi-asserted-by":"publisher","first-page":"ofac300","DOI":"10.1093\/ofid\/ofac300","volume":"9","author":"JM McLaughlin","year":"2022","unstructured":"McLaughlin, J. M., F. Khan, E. Begier, D. L. Swerdlow, L. Jodar, and A. R. Falsey. 2022. Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases 9:ofac300.","journal-title":"Open Forum Infectious Diseases"},{"key":"1968_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1080\/14760584.2024.2410898","volume":"23","author":"A Mizukami","year":"2024","unstructured":"Mizukami, A., V. Preckler, F. Verelst, T. Matsuki, Y. Ho, and D. Kurai et al. 2024. Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults\u2009\u2265\u200960 years old in Japan. Expert Review Of Vaccines 23:986\u2013996.","journal-title":"Expert Review Of Vaccines"},{"key":"1968_CR5","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/ciab595","volume":"74","author":"AR Branche","year":"2022","unstructured":"Branche, A. R., L. Saiman, E. E. Walsh, A. R. Falsey, W. D. Sieling, and W. Greendyke et al. 2022. Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017\u20132020. Clinical Infectious Diseases 74:1004\u20131011.","journal-title":"Clinical Infectious Diseases"},{"key":"1968_CR6","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1093\/infdis\/jiad510","volume":"229","author":"R Osei-Yeboah","year":"2024","unstructured":"Osei-Yeboah, R., C. K. Johannesen, A. M. Egeskov-Cavling, J. Chen, T. Lehtonen, and A. U. Fornes et al. 2024. Respiratory Syncytial Virus-Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study. Journal Of Infectious Diseases 229:S70\u2013S77.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR7","doi-asserted-by":"publisher","first-page":"e13031","DOI":"10.1111\/irv.13031","volume":"17","author":"M Savic","year":"2023","unstructured":"Savic, M., Y. Penders, T. Shi, A. Branche, and J. Y. Pir\u00e7on. 2023. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis. Influenza And Other Respiratory Viruses 17:e13031.","journal-title":"Influenza And Other Respiratory Viruses"},{"key":"1968_CR8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/infdis\/jiad189","volume":"228","author":"R Osei-Yeboah","year":"2023","unstructured":"Osei-Yeboah, R., P. Spreeuwenberg, M. Del Riccio, T. K. Fischer, A. M. Egeskov-Cavling, and H. B\u00f8\u00e5s et al. 2023. Estimation of the Number of Respiratory Syncytial Virus-Associated Hospitalizations in Adults in the European Union. Journal Of Infectious Diseases 228:1539\u20131548.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR9","doi-asserted-by":"publisher","first-page":"e0297608","DOI":"10.1371\/journal.pone.0297608","volume":"19","author":"A Domnich","year":"2024","unstructured":"Domnich, A., and G. E. Calabr\u00f2. 2024. Epidemiology and burden of respiratory syncytial virus in Italian adults: A systematic review and meta-analysis. PLoS One 19:e0297608.","journal-title":"PLoS One"},{"key":"1968_CR10","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/infdis\/jiab040","volume":"226","author":"T Shi","year":"2022","unstructured":"Shi, T., S. Vennard, F. Jasiewicz, R. Brogden, H. Nair, and RESCEU Investigators. 2022. Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity: A Systematic Review and Meta-Analysis. Journal Of Infectious Diseases 226:S17\u2013S21.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR11","doi-asserted-by":"publisher","first-page":"102653","DOI":"10.1016\/j.jiph.2025.102653","volume":"18","author":"A Domnich","year":"2025","unstructured":"Domnich, A., F. Lapi, A. Orsi, P. L. Lai, L. Pestarino, and P. C. Brasesco et al. 2025. Exploring case definitions and the natural history of respiratory syncytial virus in adult outpatients: First-season results of the RESPIRA-50 study. Journal Of Infection And Public Health 18:102653.","journal-title":"Journal Of Infection And Public Health"},{"key":"1968_CR12","doi-asserted-by":"publisher","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","volume":"222","author":"T Shi","year":"2020","unstructured":"Shi, T., A. Denouel, A. K. Tietjen, I. Campbell, E. Moran, and X. Li et al. 2020. Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. Journal Of Infectious Diseases 222:S577\u2013S583.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR13","doi-asserted-by":"publisher","first-page":"220105","DOI":"10.1183\/16000617.0105-2022","volume":"31","author":"JS Nguyen-Van-Tam","year":"2022","unstructured":"Nguyen-Van-Tam, J. S., M. O\u2019Leary, E. T. Martin, E. Heijnen, B. Callendret, and R. Fleischhackl et al. 2022. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. European Respiratory Reviews 31:220105.","journal-title":"European Respiratory Reviews"},{"key":"1968_CR14","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/infdis\/jiad559","volume":"230","author":"J Carrico","year":"2024","unstructured":"Carrico, J., K. A. Hicks, E. Wilson, C. A. Panozzo, and P. Ghaswalla. 2024. The Annual Economic Burden of Respiratory Syncytial Virus in Adults in the United States. Journal Of Infectious Diseases 230:e342\u2013e352.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/diseases13030068","volume":"13","author":"A Puggina","year":"2025","unstructured":"Puggina, A., M. Dovizio, A. Domnich, A. Marijam, C. Veronesi, and C. Rizzo et al. 2025. Healthcare Resource Utilization and Economic Outcomes of RSV-Hospitalized Patients Aged\u2009\u2265\u200960 Years: A Retrospective Cohort Study. Diseases 13:68.","journal-title":"Diseases"},{"key":"1968_CR16","doi-asserted-by":"publisher","first-page":"2479334","DOI":"10.1080\/21645515.2025.2479334","volume":"21","author":"A Puggina","year":"2025","unstructured":"Puggina, A., M. Dovizio, A. Domnich, A. Marijam, C. Veronesi, and C. Rizzo et al. 2025. Demographics and Clinical Burden of Disease Among RSV-hospitalized Older Adults in Italy:A Retrospective Cohort Study. Human Vaccines & Immunotherapeutics 21:2479334.","journal-title":"Human Caccines & Immunotherapeutics"},{"key":"1968_CR17","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1093\/infdis\/jiab452","volume":"226","author":"K Korsten","year":"2022","unstructured":"Korsten, K., N. Adriaenssens, S. Coenen, C. C. Butler, T. J. M. Verheij, and L. J. Bont et al. 2022. World Health Organization Influenza-Like Illness Underestimates the Burden of Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults. Journal Of Infectious Diseases 226:S71\u2013S78.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR18","first-page":"1900140","volume":"24","author":"E S\u00e1ez-L\u00f3pez","year":"2019","unstructured":"S\u00e1ez-L\u00f3pez, E., P. Pechirra, I. Costa, P. Crist\u00f3v\u00e3o, P. Conde, and A. Machado et al. 2019. Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018. Eurosurveillance Weekly 24:1900140.","journal-title":"Eurosurveillance Weekly"},{"key":"1968_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/pubmed\/fdae066","volume":"46","author":"E Amodio","year":"2024","unstructured":"Amodio, E., M. Belluzzo, D. Genovese, M. Palermo, V. Pisciotta, and F. Vitale. 2024. What \u2018case definition\u2019 for respiratory syncytial virus infection? Results of a systematic literature review to improve surveillance among the adults. Journal of Public Health (Oxford, England) 46:326\u2013334.","journal-title":"Journal of Public Health (Oxford, England)"},{"key":"1968_CR20","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1093\/infdis\/jiad415","volume":"229","author":"AM Egeskov-Cavling","year":"2024","unstructured":"Egeskov-Cavling, A. M., C. K. Johannesen, B. Lindegaard, T. K. Fischer, and PROMISE Investigators. 2024. Underreporting and Misclassification of Respiratory Syncytial Virus\u2013Coded Hospitalization Among Adults in Denmark Between 2015\u20132016 and 2017\u20132018. Journal Of Infectious Diseases 229:S78\u2013S83.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/infdis\/jiad012","volume":"228","author":"C Onwuchekwa","year":"2023","unstructured":"Onwuchekwa, C., L. M. Moreo, S. Menon, B. Machado, D. Curcio, and W. Kalina et al. 2023. Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis. Journal Of Infectious Diseases 228:173\u2013184.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s40121-023-00792-3","volume":"12","author":"Y Li","year":"2023","unstructured":"Li, Y., D. Kulkarni, E. Begier, P. Wahi-Singh, B. Wahi-Singh, and B. Gessner et al. 2023. Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling Study. Infectious Diseases and Therapy 12:1137\u20131149.","journal-title":"Infectious Diseases and Therapy"},{"key":"1968_CR23","unstructured":"European Medicines Agency (EMA). Arexvy. (Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)). Summary of product characteristics. 2023. Available online at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arexvy. Accessed 4 Jan 2025."},{"key":"1968_CR24","unstructured":"European Medicines Agency (EMA). Abrysvo. (Respiratory syncytial virus vaccine (bivalent, recombinant)). Summary of product characteristics. 2023. Available online at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo. Accessed 4 Jan 2025"},{"key":"1968_CR25","unstructured":"European Medicines Agency (EMA). mResvia. Summary of product characteristics. 2023. Available online at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mresvia. Accessed 5 Jan 2025."},{"key":"1968_CR26","unstructured":"CDC-ACIP Vaccine Recommendations and Guidelines. ACIP Recommendations: Respiratory Syncytial Virus (RSV) Vaccine Immunizations. 2024. Available online at. https:\/\/www.cdc.gov\/acip-recs\/hcp\/vaccine-specific\/rsv.html. Accessed 7 Jan 2025."},{"key":"1968_CR27","unstructured":"Joint Committee on Vaccination and Immunisation. Respiratory syncytial virus (RSV) immunisation programme: JCVI advice, 7 June 2023. 2023. Available online at: https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-programme-jcvi-advice-7-june-2023\/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023. Accessed 7 Jan 2025."},{"key":"1968_CR28","unstructured":"Haute Autorite Sante. Technical Commission on Vaccinations. 2023. Available online at: https:\/\/www.has-sante.fr\/jcms\/c_2755844\/fr\/commission-technique-des-vaccinations. Accessed 6 Jan 2025."},{"key":"1968_CR29","unstructured":"STIKO. RSV-Impfung f\u00fcr \u00e4ltere MenschenSTIKO:1-maligeRSV-Impfungf\u00fcralle\u2009\u2265\u200975-J\u00e4hrigensowieIndikationsimpfungf\u00fcr60-bis74-J\u00e4hrigemitRisikofaktoren. 20264. Available online at: https:\/\/www.rki.de\/DE\/Themen\/Infektionskrankheiten\/Impfen\/Informationsmaterialien\/Faktenblaetter-zum-Impfen\/RSV-Impfung-Aeltere-Menschen.html. Accessed 20 July 2026."},{"key":"1968_CR30","unstructured":"Ministero della Salute. OGGETTO: Misure di prevenzione e immunizzazione contro il virus respiratorio sinciziale (VRS). 2024. Available online at: https:\/\/allegato1711563351.pdf. Accessed 4 Jan 2025."},{"key":"1968_CR31","unstructured":"Societa Italiana di Pediatria. 2025. Raccomandazioni del Board del Calendario per la Vita sulla vaccinazione contro Virus Respiratorio Sinciziale (VRS o RSV) nella popolazione anziana e negli adulti a rischio. Available online at: https:\/\/www.igienistionline.it\/docs\/2024\/01pp.pdf. Accessed 7 Jan 2025."},{"key":"1968_CR32","unstructured":"Societa Italiana di Pediatria. CALENDARIO VACCINALE PER LA VITA 5\u00b0 EDIZIONE. 2025 edition. Available online at: https:\/\/www.allegato1734447981.pdf. Accessed 5 Jan 2025."},{"key":"1968_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/infdis\/jiac327","volume":"227","author":"I Leroux-Roels","year":"2023","unstructured":"Leroux-Roels, I., M. G. Davis, K. Steenackers, B. Essink, C. Vandermeulen, and C. Fogarty et al. 2023. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1\/2 Randomized Clinical Trial. Journal Of Infectious Diseases 227:761\u2013772.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi, A., M. G. Ison, J. M. Langley, D. G. Lee, I. Leroux-Roels, and F. Martinon-Torres et al. 2023. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. New England Journal Of Medicine 388:595\u2013608.","journal-title":"New England Journal Of Medicine"},{"key":"1968_CR35","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/cid\/ciae010","volume":"78","author":"MG Ison","year":"2024","unstructured":"Ison, M. G., A. Papi, E. Athan, R. G. Feldman, J. M. Langley, and D. G. Lee et al. 2024. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clinical Infectious Diseases 78:1732\u20131744.","journal-title":"Clinical Infectious Diseases"},{"key":"1968_CR36","unstructured":"Ministero della Salute. Prevenzione e controllo dell\u2019influenza: raccomandazioni per la stagione 2023\u20132024. Available online at: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=2023&codLeg=93294&parte=1%20&serie=null. Accessed 16 Jan 2025."},{"key":"1968_CR37","first-page":"E1","volume":"65","author":"GE Calabr\u00f2","year":"2024","unstructured":"Calabr\u00f2, G. E., C. Rizzo, A. Domnich, C. DE Waure, F. Rumi, and P. Bonanni et al. 2024. Health Technology Assessment del vaccino ricombinante adiuvato contro il virus respiratorio sinciziale (Arexvy\u00ae). Journal Of Preventive Medicine And Hygiene 65:E1\u2013E159.","journal-title":"Journal Of Preventive Medicine And Hygiene"},{"key":"1968_CR38","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/vaccines13030212","volume":"13","author":"A Puggina","year":"2025","unstructured":"Puggina, A., F. Rumi, E. Zarkadoulas, A. Marijam, and G. E. Calabr\u00f3. 2025. The Potential Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Older Adults in Italy. Vaccines (Basel) 13:212.","journal-title":"Vaccines (Basel)"},{"key":"1968_CR39","unstructured":"Ison, M. G., A. Papi, E. Athan, R. G. Feldman, J. M. Langley, and D. G. Lee et al. 2024. The efficacy of a single dose of the respiratory synctial virus prefusion F protein vaccine in adults\u2009\u2265\u200960 years of age over 3 RSV seasons. In CHEST 2024 (October 6\u20139, 2024). Boston, United States."},{"key":"1968_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S2213-2600(25)00048-7","volume":"13","author":"MG Ison","year":"2025","unstructured":"Ison, M. G., A. Papi, E. Athan, R. G. Feldman, J. M. Langley, and D. G. Lee et al. 2025. Efficacy, Safety, and Immunogenicity of the AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over Three Respiratory Syncytial Virus Seasons (AReSVi-006): a Multicentre, Randomised, Observer-Blinded, Placebo-Controlled, Phase 3 Trial. Lancet Respiratory Medicine 13:517\u2013529.","journal-title":"Lancet Respir Med"},{"key":"1968_CR41","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.1016\/j.jval.2023.09.1305","volume":"26","author":"A Puggina","year":"2023","unstructured":"Puggina, A., G. E. Calabr\u00f2, R. Santacroce, F. Rumi, L. Elliot, and M. Basile et al. 2023. EPH264 The Potential Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Adults Aged 60 and Older in Italy: Preliminary Results of a Markov Model Analysis. Value in Health 26:S251.","journal-title":"Value in Health"},{"key":"1968_CR42","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40121-024-00939-w","volume":"13","author":"D Molnar","year":"2024","unstructured":"Molnar, D., E. M. La, F. Verelst, S. Poston, J. Graham, and L. A. Van Bellinghen et al. 2024. Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious Diseases and Therapy 13:827\u2013844.","journal-title":"Infectious Diseases and Therapy"},{"key":"1968_CR43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/14760584.2024.2323128","volume":"23","author":"D Kurai","year":"2024","unstructured":"Kurai, D., A. Mizukami, V. Preckler, F. Verelst, D. Molnar, and T. Matsuki et al. 2024. The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged\u2009\u2265\u200960 years in Japan: results of a Markov model analysis. Expert Review Of Vaccines 23:303\u2013311.","journal-title":"Expert Review Of Vaccines"},{"key":"1968_CR44","doi-asserted-by":"publisher","first-page":"2432745","DOI":"10.1080\/21645515.2024.2432745","volume":"20","author":"EM La","year":"2024","unstructured":"La, E. M., J. Graham, D. Singer, D. Molnar, S. Poston, and D. Curran et al. 2024. Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged\u2009\u2265\u200960 years in the United States. Human Vaccines & Immunotherapeutics 20:2432745.","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"1968_CR45","unstructured":"Italian Medicine Agency. Guidelines for submitting Health Economic Evaluations to AIFA for pricing and reimbursement of medicines (Section E of the dossier). 2019. Available online at: https:\/\/www.aifa.gov.it\/en\/linea-guida-capitolo-9. Accessed 16 Jan 2025."},{"key":"1968_CR46","unstructured":"Istituto Nazionale di Statistica (Istat). Population and households. Population: Resident population on 1st January by age. 2023. Available online at: https:\/\/www.istat.it\/en\/population-and-households?data-and-indicators. Accessed 14 Jan 2025."},{"key":"1968_CR47","unstructured":"Ministero della Salute. Flu Vaccination- Average Vaccination Coverages. Available online at: https:\/\/www.salute.gov.it\/new\/it\/banche-dati\/vaccinazione-antinfluenzale-coperture-vaccinali-medie\/. Accessed 15 Jan 2025."},{"key":"1968_CR48","doi-asserted-by":"publisher","first-page":"2002688","DOI":"10.1183\/13993003.02688-2020","volume":"57","author":"K Korsten","year":"2021","unstructured":"Korsten, K., N. Adriaenssens, S. Coenen, C. Butler, B. Ravanfar, and H. Rutter et al. 2021. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. European Respiratory Journal 57:2002688.","journal-title":"European Respiratory Journal"},{"key":"1968_CR49","unstructured":"Influnews. Sorveglianza delle sindromi simil-influenzali in Lombardia. Stagione: settimana 19-2022 - settimana 09-2023. In Archivio gennaio-novembre 2023. Available online at: https:\/\/www.regione.lombardia.it\/wps\/portal\/istituzionale\/HP\/DettaglioServizio\/servizi-e-informazioni\/Enti-e-Operatori\/sistema-welfare\/Promozione-della-salute\/informazioni-influenza-influnews\/informazioni-influenza-influnews. Accessed 6 Jan 2025."},{"key":"1968_CR50","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1007\/s10238-022-00973-3","volume":"23","author":"A Pierangeli","year":"2023","unstructured":"Pierangeli, A., A. Piralla, S. Uceda Renteria, G. Giacomel, G. Lunghi, and E. Pagani et al. 2023. Multicenter epidemiological investigation and genetic characterization of respiratory syncytial virus and metapneumovirus infections in the pre-pandemic 2018\u20132019 season in northern and central Italy. Clinical and Experimental Medicine 23:2725\u20132737.","journal-title":"Clinical and Experimental Medicine"},{"key":"1968_CR51","unstructured":"Ministero della Salute. Nomenclatori e tariffe nazionali delle prestazioni del SSN. 2025. Available online at: https:\/\/www.salute.gov.it\/new\/it\/tema\/programmazione-e-finanziamento-del-ssn\/tariffari-nazionali-delle-prestazioni-del-ssn\/ori_e_tariffe_nazionali_delle_prestazioni_del_SSN. Accessed 7 Jan 2025."},{"key":"1968_CR52","first-page":"19","volume":"12","author":"A Potena","year":"2008","unstructured":"Potena, A., M. Simoni, M. Cellini, A. Cartabellotta, L. Ballerin, and M. Piattella et al. 2008. Management of community-acquired pneumonia by trained family general practitioners. The International Journal Of Tuberculosis And Lung Disease 12:19\u201325.","journal-title":"The International Journal Of Tuberculosis And Lung Disease"},{"key":"1968_CR53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.rmed.2018.07.001","volume":"141","author":"RW Dal Negro","year":"2018","unstructured":"Dal Negro, R. W., P. Turco, and M. Povero. 2018. Cost of influenza and influenza-like syndromes (I-LSs) in Italy: Results of a cross-sectional telephone survey on a representative sample of general population. Respiratory Medicine 141:144\u2013149.","journal-title":"Respiratory Medicine"},{"key":"1968_CR54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF03320561","volume":"8","author":"R Ravasio","year":"2006","unstructured":"Ravasio, R., C. Lucioni, and G. Chirico. 2006. Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa et\u00e0 gestazionale. Pharmacoeconomics-Ital-Res-Articles 8:105\u2013117.","journal-title":"Pharmacoeconomics-Ital-Res-Articles"},{"key":"1968_CR55","unstructured":"Istat.it. Italian Consumer Price Index for October 2024. Available at: https:\/\/rivaluta.istat.it\/Rivaluta\/. Accessed 7 Jan 2025."},{"key":"1968_CR56","doi-asserted-by":"crossref","unstructured":"Scalone, L., P. A. Cortesi, R. Ciampichini, G. Cesana, and L. G. Mantovani. 2015. Health Related Quality of Life norm data of the Italian general population: results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiology Biostatistics and Public Health 12:e11457-1\u2013e11457-15.","DOI":"10.2427\/11457"},{"key":"1968_CR57","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1093\/infdis\/jiac069","volume":"226","author":"Z Mao","year":"2022","unstructured":"Mao, Z., X. Li, K. Korsten, L. Bont, C. Butler, and J. Wildenbeest et al. 2022. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults. Journal Of Infectious Diseases 226:S87\u2013S94.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR58","unstructured":"Istituto Superiore di Sanit\u00e0. EpiCentro-L\u2019epidemiologia per la sanit\u00e0 pubblica. 2023. La sorveglianza Passi d\u2019Argento. Available online at: https:\/\/www.epicentro.iss.it\/passi-argento\/dati\/croniche. Accessed 15 Jan 2025."},{"key":"1968_CR59","unstructured":"Vaccinazione, antinfluenzale. 2024. 2023\u20132024. Dosi Vaccinali per Regione. Available online at: https:\/\/www.salute.gov.it\/new\/sites\/default\/files\/imported\/C_17_bancheDati_37_1_0_file.pdf. Accessed 6 Jan 2025."},{"key":"1968_CR60","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","volume":"26","author":"C McCabe","year":"2008","unstructured":"McCabe, C., K. Claxton, and A. J. Culyer. 2008. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26:733\u2013744.","journal-title":"Pharmacoeconomics"},{"key":"1968_CR61","doi-asserted-by":"publisher","first-page":"A88","DOI":"10.1016\/j.jval.2015.03.517","volume":"18","author":"M Griffiths","year":"2015","unstructured":"Griffiths, M., M. Maruszczak, and J. Kusel. 2015. The who-choice cost-effectiveness Threshold: a Country-level analysis of changes over time. Value in Health 18:A88.","journal-title":"Value in Health"},{"key":"1968_CR62","unstructured":"World Bank Groups. Data Bank World Development Indicators. Available online at: https:\/\/databank.worldbank.org\/reports.aspx?source=2&series=NY.GDP.PCAP.CD&country=ITA. Accessed 6 Jan 2025."},{"key":"1968_CR63","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/14760584.2022.2021880","volume":"21","author":"C de Waure","year":"2022","unstructured":"de Waure, C., G. E. Calabr\u00f2, and W. Ricciardi. 2022. Recommendations to drive a value-based decision-making on vaccination. Expert Review Of Vaccines 21:289\u2013296.","journal-title":"Expert Review Of Vaccines"},{"key":"1968_CR64","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40258-021-00683-z","volume":"20","author":"E Bell","year":"2022","unstructured":"Bell, E., M. Neri, and L. Steuten. 2022. Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward. Applied Health Economics And Health Policy 20:105\u2013117.","journal-title":"Applied Health Economics And Health Policy"},{"key":"1968_CR65","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.vaccine.2024.06.017","volume":"42","author":"M Hasso-Agopsowicz","year":"2024","unstructured":"Hasso-Agopsowicz, M., E. Sparrow, A. M. Cameron, H. Sati, P. Srikantiah, and S. Gottlieb et al. 2024. The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens. Vaccine 42:S1\u2013S8.","journal-title":"Vaccine"},{"key":"1968_CR66","doi-asserted-by":"crossref","unstructured":"Chandler, R., N. Montenegro, C. Llorach, D. Quinn, L. Noriega-Aguirre, and M. Bensellam et al. 2022. 2139. Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults. Open Forum Infectious Diseases 9:S864\u2013S865.","DOI":"10.1093\/ofid\/ofac492.1759"},{"key":"1968_CR67","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/cid\/ciae365","volume":"79","author":"R Clark","year":"2024","unstructured":"Clark, R., S. Davies, J. Labrador, P. Loubet, S. Natalini Mart\u00ednez, and H. M. Mor\u00ed\u00f1igo et al. 2024. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial. Clinical Infectious Diseases 79:1088\u20131098.","journal-title":"Clinical Infectious Diseases"},{"key":"1968_CR68","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40121-024-00985-4","volume":"13","author":"R Buynak","year":"2024","unstructured":"Buynak, R., K. Cannon, D. DeAtkine, J. Kirby, L. Usdan, and A. Bhavsar et al. 2024. Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged\u2009\u2265\u200965. Infectious Diseases and Therapy 13:1789\u20131805.","journal-title":"Infectious Diseases and Therapy"},{"key":"1968_CR69","unstructured":"Ministero della Salute. Vaccinazioni- Calendario vaccinale. Available online at:https:\/\/www.salute.gov.it\/portale\/vaccinazioni\/dettaglioContenutiVaccinazioni.jsp?lingua=italiano&id=4829&area=vaccinazioni&menu=vuoto. Accessed 6 Jan 2025."},{"key":"1968_CR70","unstructured":"Ministero della Salute. Piano Nazionale di Prevenzione Vaccinale 2023\u20132025. Available online at: https:\/\/www.salute.gov.it\/new\/it\/tema\/vaccinazioni\/piano-nazionale-prevenzione-vaccinale\/. Accessed 17 Feb 2025."},{"key":"1968_CR71","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/vaccines11050990","volume":"11","author":"MJ Postma","year":"2023","unstructured":"Postma, M. J., C. Y. Cheng, N. C. Buyukkaramikli, L. Hernandez Pastor, I. Vandersmissen, and T. Van Effelterre et al. 2023. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults\u2009\u2265\u200960 Years in Belgium. Vaccines (Basel) 11:990.","journal-title":"Vaccines (Basel)"},{"key":"1968_CR72","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1093\/infdis\/jiab118","volume":"226","author":"F Zeevat","year":"2022","unstructured":"Zeevat, F., J. Luttjeboer, J. H. J. Paulissen, J. van der Schans, P. Beutels, and C. Boersma et al. 2022. Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom. Journal Of Infectious Diseases 226:S102\u2013S109.","journal-title":"Journal Of Infectious Diseases"},{"key":"1968_CR73","unstructured":"Advisory Committee on Immunization Practices (ACIP). ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged\u2009\u2265\u200975 years and in Adults Aged 60\u201374 at Increased Risk of Severe RSV Disease. Available at: https:\/\/cdc.gov\/acip\/evidence-to-recommendations\/protein-subunit-rsv-vaccines-older-adults-etr.html. Accessed 23 Jan 2025."},{"key":"1968_CR74","unstructured":"Robert Koch Institut. Epidemiologisches Bulletin. 2024. Available at: https:\/\/www.rki.de\/DE\/Aktuelles\/Publikationen\/Epidemiologisches-Bulletin\/2024\/32_24.pdf?__blob=publicationFile&v=3. Accessed 15 April 2025."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-01968-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:02:48Z","timestamp":1786078968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-026-01968-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":74,"alternative-id":["1968"],"URL":"https:\/\/doi.org\/10.1007\/s10198-026-01968-7","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AP, AM and EZ are employed by and hold financial equities in GSK. GAC is an employee of VIHTALI, a spin-off of Universit\u00e0 Cattolica del Sacro Cuore, Rome, which received funding from GSK for the study. These authors declare no other financial and non-financial relationships and activities. FR declares no financial and non-financial relationships and activities and no conflicts of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}